0001209191-22-037887.txt : 20220617 0001209191-22-037887.hdr.sgml : 20220617 20220617162709 ACCESSION NUMBER: 0001209191-22-037887 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220615 FILED AS OF DATE: 20220617 DATE AS OF CHANGE: 20220617 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Stoppel Laura CENTRAL INDEX KEY: 0001865119 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40551 FILM NUMBER: 221024231 MAIL ADDRESS: STREET 1: C/O ACUMEN PHARMACEUTICALS, INC. STREET 2: 427 PARK STREET CITY: CHARLOTTESVILLE STATE: VA ZIP: 22902 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Acumen Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001576885 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 364108129 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 427 PARK ST. CITY: CHARLOTTESVILLE STATE: VA ZIP: 22902 BUSINESS PHONE: 925-368-8508 MAIL ADDRESS: STREET 1: 427 PARK ST. CITY: CHARLOTTESVILLE STATE: VA ZIP: 22902 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-06-15 0 0001576885 Acumen Pharmaceuticals, Inc. ABOS 0001865119 Stoppel Laura C/O RA CAPITAL MANAGEMENT 200 BERKELEY STREET, 18TH FLOOR BOSTON MA 02116 1 0 0 0 Stock Option (right to buy) 3.59 2022-06-15 4 A 0 25000 0.00 A 2032-06-14 Common Stock 25000 25000 D The shares subject to the option will vest on on the earlier of June 15, 2023 or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through each such vesting date. Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II") and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, Nexus Fund II and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock. /s/ Katherine Denby, Attorney-in-Fact 2022-06-17